XNAS · EXEL

+0.99% · +$0.5800 · Vol 2.7M

Market closed · last close 4:00 PM ET · price as of 16:42:06 ET

Exelixis Inc

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

$59.02

Card

Relationship Map

Follow $EXEL

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $EXEL by email

Veridion Score

BETAHIGH CONF · 6 of 6 factors measured

Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET · EXEL

Methodology

EXEL

Exelixis Inc

Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET

67/100

Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

67/ 100

Veridion Score

Upper range · HIGH confidence · 6 of 6 factors measured

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: HIGH · 6 of 6 factors measured · Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is EXEL moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move EXEL next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Oct 8
Score
Score moved +4
63/Upper range -> 67/Upper range
Veridion score historySource
Jun 4
CongressChecking access
Donna Shalala sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Apr 16
CongressChecking access
Donna Shalala sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Feb 6
CongressChecking access
Donna Shalala purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jan 9
CongressChecking access
Donna Shalala purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access

About Exelixis Inc

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Listed since

2000

Employees

Country

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$58.07

Day high

$60.08

Day low

$57.91

Previous close

$58.44

52W high